Secondary analyses of the randomized phase III Stop & Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer.

Conclusion: We recommend continuous scheduling of both the first- and second-line chemotherapy for advanced breast cancer. PMID: 32141389 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32141389?dopt=Abstract

Source: Acta Oncologica - March 5, 2020 Category: Cancer & Oncology Authors: Claessens AKM, Erdkamp FLG, Lopez-Yurda M, Bouma JM, Rademaker-Lakhai JM, Honkoop AH, de Graaf H, Tjan-Heijnen VCG, Bos MEMM, Dutch Breast Cancer Research Group (BOOG) Tags: Acta Oncol Source Type: research